Update on the natural history and systemic treatment of psoriasis.

PubWeight™: 0.96‹?› | Rank: Top 15%

🔗 View Article (PMC 2634854)

Published in Adv Dermatol on January 01, 2008

Authors

Stephen K Richardson1, Joel M Gelfand

Author Affiliations

1: Florida State University College of Medicine/Dermatology Associates of Tallahassee, 1714 Mahan Center Boulevard, Tallahassee, FL 32308, USA.

Articles cited by this

(truncated to the top 100)

Adhesion receptors of the immune system. Nature (1990) 28.86

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 15.65

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34

Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 9.42

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49

Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep (2000) 7.61

Pathogenesis and therapy of psoriasis. Nature (2007) 6.94

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med (2001) 5.67

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39

Pathogenesis and clinical features of psoriasis. Lancet (2007) 5.01

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum (2004) 4.57

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology (1999) 4.53

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 4.19

Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 4.12

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 3.85

The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol (2000) 3.62

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol (2003) 3.28

Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol (2005) 3.18

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum (2007) 3.16

Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04

Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med (2007) 2.89

Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med (1987) 2.80

Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol (1998) 2.77

Dermal injection of immunocytes induces psoriasis. J Clin Invest (1996) 2.64

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet (1997) 2.43

Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (2006) 2.43

Personality disorders and psychiatric symptoms in psoriasis. Psychol Rep (1995) 2.42

Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum (1997) 2.40

The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol (2007) 2.32

National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis (2005) 2.25

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19

The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol (2000) 2.10

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum (2007) 2.10

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med (1995) 2.09

Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol (2004) 2.07

Malignant tumours and psoriasis: climatotherapy at the Dead Sea. Br J Dermatol (1999) 2.06

Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol (1990) 2.01

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol (2003) 1.91

Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol (2007) 1.86

Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol (2007) 1.76

Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm Rep (2003) 1.74

HLA antigens in psoriatic arthritis. J Rheumatol (1986) 1.69

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.66

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum (2006) 1.64

The risk of lymphoma in patients with psoriasis. J Invest Dermatol (2006) 1.62

Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol (1995) 1.60

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis (2005) 1.59

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol (2006) 1.59

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol (2006) 1.58

Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol (2004) 1.57

Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol (2006) 1.57

Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol (2006) 1.56

Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology (2008) 1.53

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum (2005) 1.51

Psoriasis comorbidities. J Dermatolog Treat (2008) 1.47

Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol (1990) 1.45

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther (2005) 1.45

A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet (2002) 1.45

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol (2006) 1.44

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43

Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis (2005) 1.42

Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol (2006) 1.42

Suicidal ideation in psoriasis. Int J Dermatol (1993) 1.37

Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum (2005) 1.36

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35

The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol (2007) 1.29

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol (2003) 1.26

Psoriasis: genetic associations and immune system changes. Genes Immun (2006) 1.24

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol (2005) 1.22

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis (2006) 1.21

Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med (2007) 1.20

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol (2001) 1.19

Keratinocyte growth regulation by the products of immune cells. J Exp Med (1988) 1.19

Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol (2006) 1.19

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum (2005) 1.18

CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol (2003) 1.16

Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol (2000) 1.15

The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol (2001) 1.14

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. Oncologist (1996) 1.13

Malignant tumours and psoriasis: a follow-up study. Br J Dermatol (1999) 1.13

Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol (2006) 1.11

Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol (2007) 1.09

Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol (2007) 1.08

Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol (2007) 1.05

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol (2003) 1.05

Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol (2004) 1.04

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther (2003) 1.04

Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol (1989) 1.03

Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol (2003) 1.02

Articles by these authors

Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 4.12

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J (2009) 3.93

Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ (2013) 3.22

Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol (2008) 2.95

The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol (2010) 2.90

Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol (2011) 2.36

National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29

Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol (2010) 2.29

Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol (2008) 2.25

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19

Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03

Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med (2011) 1.94

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94

Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol (2013) 1.88

Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88

Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76

Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol (2013) 1.64

Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol (2007) 1.64

Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis (2012) 1.63

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol (2011) 1.59

AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54

Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol (2013) 1.49

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48

Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol (2012) 1.37

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35

Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis (2012) 1.29

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol (2012) 1.21

Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol (2011) 1.18

Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol (2005) 1.16

Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford) (2012) 1.15

Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) (2013) 1.11

Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis (2012) 1.08

Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06

Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol (2007) 1.05

Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf (2014) 1.04

Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf (2013) 1.00

HIV-positive patients in Botswana state that mobile teledermatology is an acceptable method for receiving dermatology care. J Telemed Telecare (2011) 1.00

Long-term treatment for severe psoriasis: we're halfway there, with a long way to go. Arch Dermatol (2007) 1.00

Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma (2007) 0.97

Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatr Dermatol (2008) 0.96

Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther (2009) 0.96

Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care (2003) 0.96

Adverse cutaneous reactions to guggulipid. J Am Acad Dermatol (2005) 0.95

Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp (2012) 0.93

Dermatologist response rates to a mailed questionnaire: a randomized trial of monetary incentives. J Am Acad Dermatol (2011) 0.93

A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol (2009) 0.93

The epidemiology of sunburn in the US population in 2003. J Am Acad Dermatol (2006) 0.92

Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol (2008) 0.91

The epidemiology of atopic dermatitis. Clin Dermatol (2003) 0.91

Seeing red: flushing out instigators of niacin-associated skin toxicity. J Clin Invest (2010) 0.91

High prevalence of aquagenic wrinkling of the palms in patients with cystic fibrosis and association with measurable increases in transepidermal water loss. Pediatr Dermatol (2012) 0.90

Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol (2013) 0.89

Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need. Arch Dermatol (2010) 0.89

Reliability and validity of a photographic method for measuring facial hair density in men. Arch Dermatol (2011) 0.88

OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol (2013) 0.87

Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc (2014) 0.87

Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome. J Am Acad Dermatol (2005) 0.87

A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. Am J Cardiovasc Dis (2013) 0.86

Psoriasis and psoriatic arthritis: a public health agenda. Am J Prev Med (2013) 0.84

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol (2008) 0.84

Test characteristics of high-resolution ultrasound in the preoperative assessment of margins of basal cell and squamous cell carcinoma in patients undergoing Mohs micrographic surgery. Dermatol Surg (2008) 0.83

Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma. Leuk Lymphoma (2011) 0.83

Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009. J Rheumatol (2013) 0.82

The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol (2012) 0.82

Srcasm overexpression in psoriasis-insights into pathogenesis. J Cutan Pathol (2007) 0.81

Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis (2012) 0.81

High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. Arch Dermatol (2011) 0.79

Assessing long-term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg (2010) 0.79

Use of complementary and alternative medicine among adults with skin disease: results from a national survey. J Am Acad Dermatol (2009) 0.79

Complementary and alternative medicine for psoriasis: a qualitative review of the clinical trial literature. J Am Acad Dermatol (2009) 0.78

Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting. J Rheumatol (2013) 0.77

Epstein-Barr virus and human herpesvirus type 6 infection in patients with psoriasis. Eur J Dermatol (2006) 0.77

CD8+ lymphoma in a patient with human immunodeficiency virus. Arch Dermatol (2005) 0.77

Curcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytes. Exp Dermatol (2010) 0.77

Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. J Clin Aesthet Dermatol (2016) 0.77

Effect of wax epilation before hair removal with a long-pulsed alexandrite laser: a pilot study. Dermatol Surg (2003) 0.75

The pitfalls of a purely clinical definition of nephrogenic systemic fibrosis: comment on the article by Todd et al. Arthritis Rheum (2008) 0.75

Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply. JAMA Dermatol (2013) 0.75

Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining. Dermatol Surg (2016) 0.75

Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis. Arch Dermatol (2012) 0.75

Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol (2012) 0.75

A randomized, double-blind, placebo-controlled proof of concept trial of topical cidofovir, 1% and 3%, for the prevention of beard hair growth in men. Arch Dermatol (2012) 0.75

Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images. Clin Nucl Med (2015) 0.75

Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists' perspective: a report from the GRAPPA 2011 annual meeting. J Rheumatol (2012) 0.75

The role of topical therapy for patients with extensive psoriasis. Cutis (2007) 0.75

A randomized, double-blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effective local anesthesia during Mohs micrographic surgery for skin cancers. J Am Acad Dermatol (2009) 0.75